title: Extracellular signal-regulated kinase 1/2 activation counteracts morphine tolerance in the periaqueductal gray of the rat.
abstract: Repeated administration of opioids produces long-lasting changes in micro-opioid receptor (MOR) signaling that underlie behavioral changes such as tolerance. Mitogen-activated protein kinase (MAPK) pathways, including MAPK extracellular signal-regulated kinases (ERK1/2), are modulated by opioids and are known to produce long-lasting changes in cell signaling. Thus, we tested the hypothesis that ERK1/2 activation contributes to the development and/or expression of morphine tolerance mediated by the periaqueductal gray (PAG). Changes in phosphorylated ERK1/2 expression were assessed with confocal microscopy and compared to behavioral measures of tolerance to the antinociceptive effects of chronic morphine administration. Repeated microinjection of morphine into the PAG produced tolerance and caused a significant increase in ERK1/2 phosphorylation, an effect not evident with acute morphine microinjection. Microinjection of the MAPK/ERK kinase inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene ethanolate (U0126), into the PAG had no effect on antinociception produced by acute morphine administration. However, repeated coadministration of U0126 and morphine into the PAG blocked ERK1/2 phosphorylation and enhanced the development of morphine tolerance. Coadministration of U0126 with morphine only on the test day also enhanced the expression of morphine tolerance. Administration of the irreversible opioid receptor antagonist beta-chlornaltrexamine blocked the activation of ERK1/2 caused by repeated morphine microinjections, demonstrating that ERK1/2 activation was a MOR-mediated event. In summary, these studies show that chronic morphine administration alters ERK1/2 signaling and that disruption of ERK1/2 signaling enhances both the development and expression of morphine tolerance. Contrary to expectations, these data indicate that ERK1/2 activation opposes the development of morphine tolerance.
authors.affiliation: Department of Psychology, Washington State University Vancouver, Vancouver, Washington 98686, USA.
authors.forename: Tara A
authors.initials: TA
authors.lastname: Macey
authors.forename: Erin N
authors.initials: EN
authors.lastname: Bobeck
authors.forename: Deborah M
authors.initials: DM
authors.lastname: Hegarty
authors.forename: Sue A
authors.initials: SA
authors.lastname: Aicher
authors.forename: Susan L
authors.initials: SL
authors.lastname: Ingram
authors.forename: Michael M
authors.initials: MM
authors.lastname: Morgan
mesh_terms: D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D004361:Drug Tolerance; D004789:Enzyme Activation / Q000187:drug effects*; D007150:Immunohistochemistry; D008297:Male; D008845:Microinjections; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009020:Morphine / Q000494:pharmacology*; D010147:Pain Measurement / Q000187:drug effects; D010487:Periaqueductal Gray / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000701:Analgesics, Opioid; D009020:Morphine; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3
references.citation: Curr Opin Neurobiol. 2004 Jun;14(3):311-7
references.pmid: 15194111
references.citation: Pain. 1989 Oct;39(1):103-107
references.pmid: 2812847
references.citation: J Physiol. 1999 Apr 1;516 ( Pt 1):219-25
references.pmid: 10066936
references.citation: Neuropharmacology. 2007 Jun;52(8):1580-5
references.pmid: 17445843
references.citation: Physiol Rev. 2001 Jan;81(1):299-343
references.pmid: 11152760
references.citation: Brain Res. 1976 Feb 27;103(3):501-13
references.pmid: 1252940
references.citation: Brain Res. 2005 Jun 14;1047(1):65-71
references.pmid: 15878767
references.citation: J Neurochem. 2000 Jan;74(1):414-22
references.pmid: 10617147
references.citation: Behav Neurosci. 1999 Aug;113(4):833-9
references.pmid: 10495091
references.citation: Eur J Neurosci. 2001 Oct;14(7):1091-104
references.pmid: 11683901
references.citation: J Neurochem. 1998 Feb;70(2):635-45
references.pmid: 9453557
references.citation: Pharmacol Biochem Behav. 2007 Nov;88(1):39-46
references.pmid: 17764731
references.citation: Pharmacol Biochem Behav. 2006 Sep;85(1):214-9
references.pmid: 16979226
references.citation: Eur J Biochem. 2003 Aug;270(16):3291-9
references.pmid: 12899687
references.citation: Curr Opin Pharmacol. 2005 Feb;5(1):60-8
references.pmid: 15661627
references.citation: Neuropsychopharmacology. 2008 Sep;33(10):2494-504
references.pmid: 18046309
references.citation: FEBS Lett. 2001 Jul 27;502(1-2):21-4
references.pmid: 11478941
references.citation: Brain Res. 2005 Oct 19;1059(2):173-8
references.pmid: 16182261
references.citation: J Pharmacol Exp Ther. 2004 Aug;310(2):774-82
references.pmid: 15056728
references.citation: FASEB J. 2007 Aug;21(10):2455-65
references.pmid: 17384143
references.citation: Nat Rev Neurosci. 2004 Mar;5(3):173-83
references.pmid: 14976517
references.citation: Neuron. 2002 May 30;34(5):807-20
references.pmid: 12062026
references.citation: Neurosci Lett. 2002 May 17;324(2):97-100
references.pmid: 11988336
references.citation: J Neurosci. 1998 Dec 15;18(24):10269-76
references.pmid: 9852564
references.citation: J Neurosci. 2005 Mar 23;25(12):3192-8
references.pmid: 15788776
references.citation: Cell Signal. 1997 May-Jun;9(3-4):237-48
references.pmid: 9218123
references.citation: J Comp Neurol. 2001 Feb 5;430(2):200-8
references.pmid: 11135256
references.citation: Brain Res. 1987 Oct 27;424(2):311-9
references.pmid: 3676830
references.citation: Eur J Pharmacol. 2006 Jun 6;539(1-2):49-56
references.pmid: 16678156
references.citation: J Biol Chem. 2006 Nov 10;281(45):34515-24
references.pmid: 16982618
references.citation: J Pharmacol Exp Ther. 2001 Sep;298(3):865-72
references.pmid: 11504778
references.citation: J Biol Chem. 2005 Jul 29;280(30):27662-9
references.pmid: 15944153
references.citation: Biochem Pharmacol. 1997 Oct 1;54(7):809-18
references.pmid: 9353135
references.citation: Eur J Neurosci. 1998 Mar;10(3):1196-201
references.pmid: 9753188
references.citation: J Neurosci. 1996 Aug 1;16(15):4707-15
references.pmid: 8764658
references.citation: J Neurosci. 1995 Feb;15(2):1285-97
references.pmid: 7532701
references.citation: J Neurochem. 2004 Jul;90(1):220-30
references.pmid: 15198681